{"protocolSection": {"identificationModule": {"nctId": "NCT01887353", "orgStudyIdInfo": {"id": "1024475"}, "organization": {"fullName": "Intermountain Health Care, Inc.", "class": "OTHER"}, "briefTitle": "The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure", "officialTitle": "A Randomized, Double-blind, Placebo Controlled Study, Designed to Investigate the Effect of Ranolazine on Left Ventricular Diastolic Function in Patients With Symptomatic AF and Preserved Ejection Function, After the Subject Has Undergone a Successful External Electrical Cardioversion", "acronym": "RAD HF"}, "statusModule": {"statusVerifiedDate": "2015-04", "overallStatus": "TERMINATED", "whyStopped": "Difficultly in enrolling", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-06"}, "primaryCompletionDateStruct": {"date": "2014-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-06-24", "studyFirstSubmitQcDate": "2013-06-25", "studyFirstPostDateStruct": {"date": "2013-06-26", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-04-09", "resultsFirstSubmitQcDate": "2015-07-15", "resultsFirstPostDateStruct": {"date": "2015-07-20", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-07-15", "lastUpdatePostDateStruct": {"date": "2015-07-20", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Intermountain Health Care, Inc.", "class": "OTHER"}, "collaborators": [{"name": "Gilead Sciences", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the efficacy of ranolazine in the prevention of recurrent atrial fibrillation in post-cardioversion patients with heart failure and preserved ejection fraction."}, "conditionsModule": {"conditions": ["Atrial Fibrillation", "Heart Failure"], "keywords": ["atrial fibrillation", "heart failure", "ranolazine", "cardioversion", "persistent AF", "paroxysmal AF"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 8, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Ranolazine", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Ranolazine"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Ranolazine", "description": "Patients will take ranolazine 1000 mg tablets twice daily", "armGroupLabels": ["Ranolazine"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo pill manufactured to mimic ranolazine 1000 mg tablets. Patients will be instructed to take two pills a day.", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Time to First Atrial Fibrillation (AF) Recurrence", "description": "There were too few participants for an assessment of time to first recurrence, therefore the numbers of participants with recurrence up to 6 months is reported instead", "timeFrame": "up to 6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or non-pregnant female \\> 18 years of age;\n* Documentation of heart failure and who are in NYHA class II or III;\n* Documented history of symptomatic AF \\< 6 months in duration at the time of presentation, currently in AF at the time of the external electrical cardioversion, and successfully restored to normal sinus rhythm;\n* Percutaneous coronary intervention (PCI) patients who can be placed on anticoagulation with warfarin post-cardioversion (and not on rivaroxaban or dabigatran);\n* Demonstration of preserved ejection fraction (EF) by echocardiography;\n* Echocardiographic evidence of impaired diastolic filling.\n\nExclusion Criteria:\n\n* Known history of permanent or long-standing AF (\\> 6 months);\n* Other acutely reversible causes of AF, including but not limited to: hyperthyroidism, pericarditis, myocarditis or pulmonary embolism;\n* Known history of cirrhosis;\n* NYHA Class IV;\n* Myocardial Infarction, unstable angina, or coronary artery bypass graft surgery within three months prior to screening;\n* Percutaneous coronary intervention (PCI) within 4 weeks prior to screening, if these patients need to be placed on rivaroxaban or dabigatran post-cardioversion;\n* Clinically significant valvular disease;\n* Clinically significant pulmonary disease;\n* Stroke within 3 months prior to screening;\n* Creatinine clearance \\< 30 mL/min as calculated by Cockcroft-Gault formula;\n* Use of anti-arrhythmic drugs (Class Ia or IIIc) within 3 months prior to screening;\n* Concurrent use of drugs considered strong inhibitors of CYP3A;\n* Concurrent use of drugs considered as CYP3A inducers;\n* Prior treatment with ranolazine.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "T. Jared Bunch, MD", "affiliation": "Intermountain Medical Center", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Intermountain Medical Center", "city": "Murray", "state": "Utah", "zip": "84107-5701", "country": "United States", "geoPoint": {"lat": 40.66689, "lon": -111.88799}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Ranolazine", "description": "Ranolazine: Patients will take ranolazine 1000 mg tablets twice daily"}, {"id": "FG001", "title": "Placebo", "description": "Placebo: Placebo pill manufactured to mimic ranolazine 1000 mg tablets. Patients will be instructed to take two pills a day."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "Study was stopped early because of difficulty recruiting.", "numSubjects": "0"}, {"groupId": "FG001", "comment": "Study was stopped early because of difficulty recruiting.", "numSubjects": "1"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Study stopped early", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Ranolazine", "description": "Ranolazine: Patients will take ranolazine 1000 mg tablets twice daily"}, {"id": "BG001", "title": "Placebo", "description": "Placebo: Placebo pill manufactured to mimic ranolazine 1000 mg tablets. Patients will be instructed to take two pills a day."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "8"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "89.7", "spread": "9.5"}, {"groupId": "BG001", "value": "78.9", "spread": "8.9"}, {"groupId": "BG002", "value": "84.3", "spread": "9.2"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "5"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "8"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "8"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Time to First Atrial Fibrillation (AF) Recurrence", "description": "There were too few participants for an assessment of time to first recurrence, therefore the numbers of participants with recurrence up to 6 months is reported instead", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "up to 6 months", "groups": [{"id": "OG000", "title": "Ranolazine", "description": "Ranolazine: Patients will take ranolazine 1000 mg tablets twice daily"}, {"id": "OG001", "title": "Placebo", "description": "Placebo: Placebo pill manufactured to mimic ranolazine 1000 mg tablets. Patients will be instructed to take two pills a day."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "4"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Entire study duration (up to 6 months or until stoppage).", "eventGroups": [{"id": "EG000", "title": "Ranolazine", "description": "Ranolazine: Patients will take ranolazine 1000 mg tablets twice daily", "seriousNumAffected": 0, "seriousNumAtRisk": 4, "otherNumAffected": 1, "otherNumAtRisk": 4}, {"id": "EG001", "title": "Placebo", "description": "Placebo: Placebo pill manufactured to mimic ranolazine 1000 mg tablets. Patients will be instructed to take two pills a day.", "seriousNumAffected": 0, "seriousNumAtRisk": 4, "otherNumAffected": 2, "otherNumAtRisk": 4}], "otherEvents": [{"term": "Medication intolerance", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 4}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 4}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "T. Jared Bunch", "organization": "Intermountain Healthcare", "email": "jared.bunch@imail.org", "phone": "8015074701"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}, {"id": "D000001281", "term": "Atrial Fibrillation"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000001145", "term": "Arrhythmias, Cardiac"}, {"id": "D000010335", "term": "Pathologic Processes"}], "browseLeaves": [{"id": "M4586", "name": "Atrial Fibrillation", "asFound": "Atrial Fibrillation", "relevance": "HIGH"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M27580", "name": "Heart Failure, Diastolic", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M4453", "name": "Arrhythmias, Cardiac", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069458", "term": "Ranolazine"}], "ancestors": [{"id": "D000026941", "term": "Sodium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M427", "name": "Ranolazine", "asFound": "Toddlers", "relevance": "HIGH"}, {"id": "M23177", "name": "Sodium Channel Blockers", "relevance": "LOW"}, {"id": "M30025", "name": "Diuretics, Potassium Sparing", "relevance": "LOW"}], "browseBranches": [{"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}